PROBIO-TEC™ includes two patented probiotics, the most studied bifidobacteria BB-12™ (Bifidobacterium animalis subsp. lactis) & LGG™ (Lactobacillus rhamnosus), the most studied probiotic strain in the whole world. The product has been specifically developed for Nôgel by world-famous probiotic developer Chr. Hansen, who is known for its LGG™. Chr. Hansen production strain has remained stable and genomically identical over the last 25 years. The LGG® strain has been described in more than 250 publications of human studies. Lab-based research has shown that the LGG® probiotic strain has high bile and acid tolerance, which may be important for a probiotic strain to survive passage through the gastrointestinal tract and for its potential beneficial effects. 68% of the product´s bacteria is patented LGG™.

The BB-12® strain has been described in depth in different health fields for infants, premature infants, children, pregnant women, adults and elderly without safety issues. The BB-12® strain from Chr. Hansen has had 100% genome stability for decades and BB-12® strain in formula products shows superior in-use stability, heat stability for administration and storage stability. Lab-based research has shown that the BB-12® strain is an excellent survivor of both gastric acid solution at pH 2.5 and 1% porcine bile solution. These characteristics enable the probiotic strain to survive the journey through the gastrointestinal tract. 32% of the product´s bacteria is patented BB-12™ bifidobacteria, that has been used in baby formula, dietary supplements and fermented milk products (such as yogurt) worldwide since 1986. 


Bifidobacteria, BB-12™ has been associated with several health benefits for infants and children:

  • Digestive health – softer and more frequent bowel movements, and shorter and fewer episodes of loose stools and overall regularity;
  • Excessive crying and fussing – significantly less excessive crying and fussing in babies;
  • Daily sleep – additional daily sleep in babies with excessive crying and fussing and an improvement in the health-related quality of life of their parents/caregivers;
  • Respiratory health – fewer episodes of respiratory discomfort;
  • Skin health – fewer instances of red, dry, and scaly skin in babies.


  • Oral health – lower salivary levels of specific bacteria that contribute to poor oral health;
  • Frequency of bowel movements – more regular bowel movements in adults and the elderly;
  • Immune health – benefits for immune system function;
  • Cholesterol levels – supporting healthy levels of cholesterol.

LGG™ has been associated with several health benefits for infants and children:

  • Loose and watery stools –  fewer instances and shorter episodes of loose and watery stools and normal bowel habits;
  • Health conditions related to hospitalization – fewer hospitalization-related digestive system issues and fewer respiratory tract discomfort that can occur following hospitalization;
  • Immune challenges related to respiratory health – LGG® has been associated with fewer respiratory challenges, fewer instances of respiratory challenges that last more than three days, and significantly less days with signs of respiratory discomfort;
  • Oral health – Based on human studies and microbiological evaluation, LGG® has been associated with more healthy teeth, and with lower levels of specific bacteria that contributes to poor oral health.


  • Travel-related loose stools – LGG® has been associated with a reduction in the incidence of loose stools that travelers commonly experience when traveling in countries, regions and areas which present more chance of being exposed to unfamiliar bacteria;
  • Immune health – LGG® probiotic supplementation has been associated with significantly higher levels of antibodies (natural proteins integral to immune system function), which suggests support for immune health.

Product is suitable for the whole family from infants to elderly. Additive free product includes only three ingredients: sunflower oil and two patented and widely clinically tested probiotic strains.

Used literature

Arvola T, et al. Pediatrics. 1999;104(5):e64.
Underwood MA, et al. Journal of Pediatric Gastroenterology and Nutrition. 2009;48(2):216-25.
Vanderhoof JA, et al. The Journal of Pediatrics. 1999;135(5):564-8.
Hojsak I, et al. Pediatrics. 2010;125(5):e1171-7.
Isolauri E, et al. Pediatrics. 1991;88(1):90-7.Gueimonde M, et al. Journal of Pediatric Gastroenterology and Nutrition. 2006;42(2):166-70.7. Lahtinen SJ, et al. J Allergy Clin Immunol. 2009;123(2):499-5019. Hatakka K, et al. J Dent Res. 2007;86(2):125-30.
Sindhu KNC, et al. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2014;58(8):1107-15.
Aggarwal S, et al. Indian J Med Res. 2014;139(3):379-85.
Hojsak I, et al. Clin Nutr. 2010;29(3):312-6.
Nase L, et al. Caries Res. 2001;35(6):412-20.
Glavina D, et al. Coll Antropol. 2012;36(1):129-32.
Davidson LE, et al. Eur J Clin Nutr. 2011;65(4):501-7.
Vos WM. 2009. Proc Natl Acad Sci United States Am 106:17193 –17198.
EFSA Panel on Biological Hazards (BIOHAZ). EFSA Journal. 2015;13:4331.
Food and Drug Administration. GRAS Notice No GRN 000049. 2002.

Daily dose

PROBIO-TEC™ daily dose is 6 drops that includes 1 billion colony-forming units of lactic acid bacteria (68% LGG™ and 32% BB-12™).


Charity is one of the most important values for Nôgel. For every product purchased we donate 5 cents to Tartu University Hospital Children´s Foundation.

PROBIO-TEC™ in our webstore